Hangzhou, Zhejiang, China, October 19, 2026 — Zhejiang Doer Biologics Co., Ltd. ("Doer Biologics"), a clinical-stage biopharmaceutical company and a controlled subsidiary of Huadong Medicine, focused on developing innovative biologic therapeutics for metabolic diseases and cancer, today announced that the results of its independently developed first-in-class (FIC) long-acting trispecific agonist DR10624 targeting fibroblast growth factor 21 receptor (FGF21R), glucagon receptor (GCGR), and glucagon-like peptide-1 receptor (GLP-1R) for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH) in a Phase II clinical study (the "DR10624-202 study") have been successfully selected as a Late Breaking Abstract (LBA) for the American Association for the Study of Liver Diseases (AASLD) Annual Meeting, The Liver Meeting® (TLM) 2026.
Professor Vincent Wai-Sun Wong, Principal Investigator of the DR10624-202 study, Associate Vice-President (Research) of The Chinese University of Hong Kong, Mok Hing Yiu Professor of Medicine, Assistant Dean (Development) of the Faculty of Medicine, and Head of the Division of Gastroenterology and Hepatology, will deliver an oral presentation (Late Breaking Parallel Presentation).
Presentation Details
Session Date / Time: 11/9/2026, 10:30 am - 12:00 pm
Title: Late Breaking Abstract Parallel Session 3
Type: Abstract Parallel
Presentation: DR10624, a First-In-Class, FGF21 Receptor/Glucagon Receptor/GLP-1 Receptor Triple Agonist, Rapidly and Significantly Reduced Liver Fat and Fibrosis Markers, and Improved Liver Functions and Lipid Profiles, in Patients With MASLD/MASH: Results of a Randomized Phase 2 Trial
Presentation Time: 10:45 am - 11:00 am
Presentation Duration: 15 minutes
Publication Number: 5014
The Late Breaking Abstract will be embargoed until 8:00 am (US local time) on November 5, 2026, and will be published on the AASLD official website. Huadong Medicine will disclose the data from the DR10624-202 study after the oral presentation.
About AASLD
The 2026 American Association for the Study of Liver Diseases Annual Meeting (AASLD TLM 2026) will be held from November 5 to 9, 2026, in Denver, Colorado, USA. The American Association for the Study of Liver Diseases (AASLD) was founded in 1950, and its annual meeting (The Liver Meeting®) is one of the largest and most academically influential liver disease academic conferences worldwide. The Late Breaking Abstract (LBA) is the most prestigious category at the AASLD Annual Meeting, with a high selection threshold requiring research content and data of major clinical significance. Each year, the LBAs at the AASLD Annual Meeting are often regarded as the highlights and bellwethers of global novel drug development for liver diseases for that year. For more conference details, please visit https://www.aasld.org/tlm-26/home
Lv Liang, Chairman and General Manager of Huadong Medicine, commented: "We are very delighted to see that the Phase II clinical research results of DR10624 have been selected for AASLD 2026 Late-Breaking Research and will be presented globally as an oral presentation. This fully reflects the outstanding innovation capabilities of Huadong Medicine and Doer Biologics in the field of drug development for metabolic and liver diseases. Huadong Medicine and Doer Biologics will continue to deepen innovative drug research and development, promote more China-originated innovative therapies to the world, and provide better treatment options for patients worldwide!"
Dr. Huang Yanshan, Founder & Chief Executive Officer of Doer Biologics, commented: "DR10624 is a first-in-class long-acting three-target agonist targeting FGF21R, GCGR, and GLP-1R. DR10624 was developed using Doer Biologics' proprietary MultipleBody® platform technology, aiming to provide comprehensive metabolic benefits for patients with metabolic diseases. Non-clinical studies have shown that DR10624 exhibits significant dose-dependent efficacy in liver protection and anti-hyperlipidemic activity in B6-Alms1-del mice (a spontaneous MASH model characterized by obesity, hyperglycemia, and dyslipidemia), and can reduce steatosis, inflammation, and ballooning, and improve NAS scores."
Dr. Fang Yongliang, Chief Operating Officer of Doer Biologics, commented: "We are pleased to announce that the DR10624-202 study has been selected as an LBA for AASLD 2026. Patients with MASLD have a higher risk of cardiovascular disease and type 2 diabetes, and MASH is a more severe form of MASLD and a major cause of liver failure worldwide. If not effectively treated, MASH can progress to cirrhosis, liver failure, and even liver cancer or death. The DR10624-202 study results to be presented at AASLD 2026 demonstrate the great potential of DR10624 in treating MASLD/MASH. We are committed to advancing DR10624 as a potential therapeutic for MASLD/MASH."
For more information about the clinical trial of the DR10624-202 study, please visit clinicaltrials.gov (NCT07024212) or www.chinadrugtrials.org.cn (CTR20250525).